Caxton Associates LLP Axsome Therapeutics, Inc. Transaction History
Caxton Associates LLP
- $2.87 Trillion
- Q1 2025
A detailed history of Caxton Associates LLP transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 2,629 shares of AXSM stock, worth $281,881. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,629Holding current value
$281,881% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding AXSM
# of Institutions
408Shares Held
36.6MCall Options Held
751KPut Options Held
568K-
Vanguard Group Inc Valley Forge, PA3.88MShares$416 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$354 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.92MShares$313 Million5.58% of portfolio
-
Bvf Inc San Francisco, CA1.69MShares$181 Million8.66% of portfolio
-
Macquarie Group LTD Australia, C3976KShares$105 Million0.14% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $4.6B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...